Scarica l'app Stockscreener
2.655
6.37%
0.145
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - BioSpace
Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Yahoo Finance
Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey
ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace
ImmunityBio Completes FDA License Application Submissions - marketscreener.com
Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com
ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com
Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - MSN
Is ImmunityBio Stock Heading Upwards? - timothysykes.com
ImmunityBio settles securities class action lawsuit for $10.5 million - Claim Depot
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Insider Monkey
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - Insider Monkey
ImmunityBio secures $75 million in direct offering - Investing.com Australia
ImmunityBio secures $75 million in direct offering By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow
ImmunityBio Stock: What’s Driving the Market? - timothysykes.com
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
ImmunityBio Launches $75 Million Registered Direct Offering - MarketScreener
ImmunityBio (IBRX) Secures $75 Million in Direct Offering - GuruFocus
ImmunityBio raises $75 million in equity financing - MSN
ImmunityBio Secures $75 Million in Direct Offering - TipRanks
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire
IMMUNITYBIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) - ACCESS Newswire
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - BioSpace
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, - GlobeNewswire
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors - TradingView
ImmunityBio: Taking Care Of Business (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio and Beigene to run Phase 3 of Anktiva plus PD-1 in NSCLC - PPF Group
Why ImmunityBio Inc. (IBRX) Went Up Last Week? - Yahoo Finance
Is ImmunityBio, Inc. Stock a Buy Right Now? - timothysykes.com
ImmunityBio’s Recent Surge: What’s Behind It? - timothysykes.com
ImmunityBio to Host Investor Day - BioSpace
Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? - Insider Monkey
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates - EIN News
ImmunityBio appoints Deloitte as new auditor By Investing.com - Investing.com South Africa
ImmunityBio appoints Deloitte as new auditor - Investing.com Australia
Drugmaker's $10.5M Deal In Investor FDA Approval Suit OK'd - Law360
ImmunityBio $10.5 Million Settlement Over Record Selloff Gets OK - Bloomberg Law News
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company
1.75%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):